Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares saw strong trading volume on Wednesday . 3,626,381 shares were traded during mid-day trading, an increase of 3,120% from the previous session’s volume of 112,616 shares.The stock last traded at $13.63 and had previously closed at $10.93.

A number of research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Voyager Therapeutics in a research report on Wednesday, May 10th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 17th. Stifel Nicolaus restated a “buy” rating and issued a $33.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, June 27th. Finally, Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, August 8th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $23.43.

The firm’s 50 day moving average is $9.03 and its 200-day moving average is $10.22. The company’s market capitalization is $366.69 million.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by $0.11. The company had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. Equities research analysts expect that Voyager Therapeutics, Inc. will post ($2.84) earnings per share for the current fiscal year.

In related news, insider Bernard Ravina sold 5,490 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $10.00, for a total value of $54,900.00. Following the completion of the sale, the insider now owns 17,157 shares of the company’s stock, valued at $171,570. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.00% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. lifted its stake in Voyager Therapeutics by 0.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock worth $261,000 after acquiring an additional 114 shares during the period. Fiduciary Trust Co. lifted its stake in Voyager Therapeutics by 0.4% in the second quarter. Fiduciary Trust Co. now owns 109,034 shares of the company’s stock worth $977,000 after acquiring an additional 473 shares during the period. Goldman Sachs Group Inc. lifted its stake in Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after acquiring an additional 1,399 shares during the period. Teachers Advisors LLC lifted its stake in Voyager Therapeutics by 9.8% in the fourth quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock worth $262,000 after acquiring an additional 1,847 shares during the period. Finally, California State Teachers Retirement System lifted its stake in Voyager Therapeutics by 8.4% in the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock worth $231,000 after acquiring an additional 2,000 shares during the period. 40.70% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/06/voyager-therapeutics-inc-vygr-sees-strong-trading-volume.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.